Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBI-v: Dabrafenib + Trametinib vs Vemurafenib in BRAF-mutant Melanoma
NCT01597908Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2012
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of dabrafenib + trametinib, trametinib in cutaneous melanoma (CM), sponsored by Novartis. Started Jun 2012; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT01597908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01597908.